Exercise as Maintenance Therapy in Advanced Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is a randomized control trial at a single institution comparing advanced lung cancer patients undergoing supervised home-based exercise program versus usual care. The intervention is a supervised home-based exercise program that will be coordinated by the MOVE program. The regimen will be 12 weeks in duration, three times a week, and administered by a trained professional virtually.
Participants will be randomized 1:1 to the exercise or usual care arm. Participants will be stratified on baseline frailty by the SPPB.
Primary Objective To compare changes patient-reported fatigue (by FACT-F survey) from baseline to post-intervention in patients with locally advanced and advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
Secondary Objectives
- To compare changes in cardiorespiratory fitness measured by VO2peak, estimated as time on the treadmill during ramp treadmill test, from baseline to post-intervention in patients with locally advanced/advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
- To compare changes in physical function measured by the short physical performance battery from baseline to post-intervention in patients with locally advanced/advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
- To compare changes in muscle mass and muscle density measured on CT scans for disease monitoring and bioimpedance analysis from baseline to post-intervention in patients with locally advanced/advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
- To compare changes in depression scores by HADS survey from baseline to post-intervention in patients with locally advanced and/or advanced lung cancer receiving maintenance immunotherapy undergoing a supervised home-based exercise program versus usual care.
- To compare the proportion of patients who are "fatigued," defined as a FACT-F score of <43 at post-intervention between the exercise and usual care arms.
- To evaluate uptake and adherence of supervised home-based exercise program in patients with locally advanced and/or advanced lung cancer receiving maintenance immunotherapy or targeted therapy, measured by the percentage of patients who consented to the study and percentage of training sessions attended by patients in the exercise arm.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Tarah J Ballinger, MD
- Email: tarahb@iu.edu
Study Contact Backup
- Name: Malori Pojar
- Phone Number: (317) 274-0930
- Email: mpojar@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Methodist Hospital
-
Indianapolis, Indiana, United States, 46202
- Sidney and Lois Eskenazi Hospital
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Known diagnosis of locally advanced (stage III) or metastatic NSCLC
Patient is currently receiving maintenance immunotherapy for at least 1 month and planned for at least 3 additional months of therapy
- Patients receiving maintenance therapy refers to patients with stable disease or partial response to therapy, including patients who have had a history of disease progression but are currently stable or responding to a different therapy
- Patients previously receiving chemotherapy are eligible as long as at least one month has elapsed since completing chemotherapy. Those currently receiving chemotherapy are not eligible.
Patient is willing and able to participate in a supervised home-based exercise program as determined by the MOVE program
a.Participants must have internet access and equipment to participate in virtual exercise
- ECOG performance status of 0-2
Exclusion Criteria:
- Already meeting exercise guidelines and participating in at least 150 minutes of moderate or vigorous exercise per IPAQ
- Unable to participate in the supervised home-based exercise program as determined by the MOVE program
Medical co-morbidities that preclude patient from participating in supervised exercise, including but not limited to:
- Advanced heart failure
- Advanced respiratory disease requiring home oxygen use
- Uncontrolled psychiatric disorders
- History of fragility fracture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Exercise Intervention
Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands. All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session. |
Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands. All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session. |
|
No Intervention: Usual Care
Participants randomized to usual care arm will receive care per their treatment team.
Usual care participants are encouraged to exercise but will not be provided components of the intervention.
Participants in the usual care arm will be given usual care handouts at baseline.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in patient-reported fatigue
Time Frame: baseline, week 12, and week 24
|
Measured by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) survey
|
baseline, week 12, and week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Uptake of the study
Time Frame: date open to accrual until closed to accrual, up to 5 years
|
the proportion of total patients approached, screened, and ultimately completing the baseline assessments
|
date open to accrual until closed to accrual, up to 5 years
|
|
Change in cardiorespiratory fitness
Time Frame: baseline, week 12, and week 24
|
Measured by VO2peak, estimated as time on the treadmill
|
baseline, week 12, and week 24
|
|
Change in physical performance battery
Time Frame: baseline, week 12, and week 24
|
total score on short physical performance battery
|
baseline, week 12, and week 24
|
|
Change in muscle mass
Time Frame: baseline, and week 12
|
measured by mg/kg2 on HU on CT scans
|
baseline, and week 12
|
|
Change in muscle density
Time Frame: baseline, and week 12
|
measured by mg/kg2 on HU on CT scans
|
baseline, and week 12
|
|
Change in depression
Time Frame: baseline, week 12, and week 24
|
measured by total score of HADS survey
|
baseline, week 12, and week 24
|
|
Proportion of patients who are "fatigued"
Time Frame: baseline, week 12, and week 24
|
measured by FACT-F score of <43
|
baseline, week 12, and week 24
|
|
Adherence with the intervention defined
Time Frame: baseline to post 12-week intervention
|
the proportion of scheduled sessions attended by participants randomized to the exercise intervention arm
|
baseline to post 12-week intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tarah J Ballinger, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTO-IUSCCC-0865
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.